ISEC Healthcare (SGX:40T) Research & Development: S$0.00 Mil (TTM As of Mar. 2026)


SGX:40T ISEC Healthcare Ltd SGX:40T
59 GF Score
Price S$0.32
GF Value S$0.45
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is ISEC Healthcare Research & Development?

ISEC Healthcare SGX:40T 59 Research & Development is S$0.00 Mil as of Mar. 2026. GuruFocus rates SGX:40T with a GF Score™ of 59/100 and a GF Value™ of S$0.45 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. ISEC Healthcare's Research & Development for the three months ended in Mar. 2026 was S$0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was S$0.00 Mil.

ISEC Healthcare  (SGX:40T) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

ISEC Healthcare Research & Development Related Terms

ISEC Healthcare Research & Development Historical Data

* Premium members only.

The historical data trend for ISEC Healthcare's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ISEC Healthcare Research & Development Chart

ISEC Healthcare Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ISEC Healthcare Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SGX:40T
59GF Score
ISEC Healthcare Ltd SGX:40T
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ISEC Healthcare Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was S$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of S$0.00 Mil mean?
ISEC Healthcare (SGX:40T) has a Research & Development of S$0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on ISEC Healthcare and its competitors.
Is ISEC Healthcare's Research & Development too high?
ISEC Healthcare's current Research & Development is S$0.00 Mil. Overall, ISEC Healthcare has a GF Score™ of 59/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ISEC Healthcare's Research & Development compare to HCA and THC?
ISEC Healthcare's Research & Development of S$0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on ISEC Healthcare and its competitors. ISEC Healthcare's current Research & Development is S$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ISEC Healthcare stock overvalued right now?
Based on GuruFocus' analysis, ISEC Healthcare (SGX:40T) is currently considered Significantly Undervalued. The stock's GF Value™ is S$0.45, compared to a current price of S$0.32 — trading 30% below its estimated fair value. The current Research & Development is S$0.00 Mil. ISEC Healthcare's overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For ISEC Healthcare (SGX:40T), the current Research & Development is S$0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ISEC Healthcare (SGX:40T) Overvalued in 2026?

Based on GuruFocus' analysis, ISEC Healthcare stock appears to be undervalued. The current stock price of S$0.32 is trading 30% below its estimated GF Value™ of S$0.45. GuruFocus considers ISEC Healthcare to be Significantly Undervalued.

Key valuation signals for SGX:40T:

  • Research & Development: S$0.00 Mil
  • GF Value™: S$0.45 vs. price of S$0.32 (30% below fair value)
  • GF Score™: 59/100 with 2 warning signs

No single metric tells the full story. See the SGX:40T stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ISEC Healthcare Business Description

Address 51 Goldhill Plaza, No. 10-07/08, Singapore, SGP, 308900
ISEC Healthcare Ltd principal activity of the Company is that of an investment holding company. It is regional provider of comprehensive medical eye care services with ambulatory surgical centres. The company has two reportable segment which are Specialised health services: provision of medical care, consultancy, treatment and surgery in the field of ophthalmology; and General health services: provision of general medical and procedural treatment services. The majority of revenue comes from Specialised health services segment. The company has presence in Singapore, Malaysia, and Myanmar. The company generates majority of revenue from Malaysia.
59GF Score

Get the complete analysis for SGX:40T

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

S$0.32
Price
S$0.45
GF Value